Álvaro Mena

Álvaro Mena

Auto-generated profile, based on publicly available information

Álvaro Mena

Internal Medicine Department, A Coruña University Hospital Complex, 15006 A Coruña, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ÁMÁlvaro Mena
Álvaro Mena
JPJosé D Pedreira
José D Pedreira
ÁCÁngeles Castro
Ángeles Castro
SLSoledad López
Soledad López
PVPilar Vázquez
Pilar Vázquez
Eva PovedaEva Poveda
Eva Poveda

6 January 2022 in AIDS
Verified
Journal Article
Closed access
MAManuel González de Aledo
Manuel González de Aledo
ACAngelina Cañizares
Angelina Cañizares
PVPilar Vázquez-Rodríguez
Pilar Vázquez-Rodríguez
ÁCÁngeles Castro
Ángeles Castro
LMLuz Moldes
Luz Moldes
ÁMÁlvaro Mena
Álvaro Mena
Objective: To evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people with HIV (PWH). Methods: Participants were evaluated 4 weeks after the second dose of mRNA-1273 or BNT162b2 vaccine. Tolerability was evaluated with a specific adverse event questionnaire. Patient's sera were analysed using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin). Results: One-hundred PWH were included, 75% of them men, with a mean age of 44 ± 11 years old, all receiving antiretroviral treatment and mostly with controlled viral loads (98% with HIV RNA 200 CD4+/μl. All patients seroconverted after vaccination (antibody concentration ≥33.8 binding antibody units [BAU]/ml). Only 3% of the patients had a low antibody concentration (2080 BAU/ml). Fifty-six patients had local or systemic symptoms, with mild arthromyalgia being the most common systemic symptom. No severe adverse events were reported. Conclusions: Vaccination with two doses of mRNA-1273 or BNT162b2 is well tolerated in PWH under effective antiretroviral treatment and it leads to a successful antibody response.

1 March 2017 in Journal of Clinical Virology
Verified
Journal Article
Open access
IRIria Rodríguez-Osorio
Iria Rodríguez-Osorio
PCPURIFICACIÓN CID-SILVA
PURIFICACIÓN CID-SILVA
LALuis E Morano Amado
Luis E Morano Amado
ÁCÁngeles Castro
Ángeles Castro
MSMarta Suárez
Marta Suárez
Eva PovedaEva Poveda
Eva Poveda
New direct-acting antivirals agents (DAAs) are very safe and well tolerated. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October 2015). A total of 120 HCV mono-infected patients were recorded. Mean age of patients was 72.6±7.4years. There were 53.3% women and GT1b was the most frequent (83.3%); 64.2% had cirrhosis and 42.5% were treatment experienced. Ombitasvir+Paritaprevir/r±Dasabuvir±Ribavirin (RBV) and sofosbuvir/ledipasvir±RBV were the most frequently used regimens. Weight-adjusted dosing of RBV was included in 61.7% and 43.6% of them required a dose reduction. Most of the patients (86.7%) had concomitant chronic medication and in 35.8% adjustment was necessary. Adverse events (AE) were seen in 65% of the patients; more frequent when a protease inhibitor (PI) was being used. The sustained virological response (SVR12) per ITT was 88.3%. Only 3 patients discontinued treatment and 2 patients died. High rates of SVR12 (88.3%) were observed among elderly patients with DAAs-based regimens. The presence of AE was frequent (65%). The majority of these patients (86.7%) had concomitant medication that required adjustment in 1/3 of them. These findings highlight the high rates of response to DAAs in the elderly HCV-population. However, special caution must be taken when using RBV and a PI.

23 February 2017 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
AMA Mena
A Mena
HMH Meijide
H Meijide
IRI Rodríguez‐Osorio
I Rodríguez‐Osorio
ACA Castro
A Castro
Eva PovedaEva Poveda
Eva Poveda

26 June 2020 in Internal and Emergency Medicine
Verified
Journal Article
Open access
PDF file
ÁDÁlvaro Dubois-Silva
Álvaro Dubois-Silva
CBCristina Barbagelata-López
Cristina Barbagelata-López
ÁMÁlvaro Mena
Álvaro Mena
PPPatricia Piñeiro-Parga
Patricia Piñeiro-Parga
DLDiego Llinares-García
Diego Llinares-García
SFSantiago Freire-Castro
Santiago Freire-Castro

13 October 2020 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
GSG Schuettfort
G Schuettfort
LBL Boekenkamp
L Boekenkamp
Alfonso Cabello-UbedaAlfonso Cabello-Ubeda
Alfonso Cabello-Ubeda
ACAg Cotter
Ag Cotter
PLP De Leuw
P De Leuw
AHAe Haberl
Ae Haberl